Hub will address manufacturing, business and regulatory challenges to ensure new targeted biological medicines can be developed quickly
Award to develop novel miRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products
LGC represented at anniversary event in Madrid
Meeting, organised by our Inorganic Analysis team, attended by delegates from across UK
Reviews 2016 activities and highlights breadth and quality of our research
Study found clear evidence that companies using NMS services have higher survival rates than control group of similar non-customers
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.